IIM
CORT icon

Illumine Investment Management’s Corcept Therapeutics CORT Stock Holding History

Illumine Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,524
Closed -$1.06M – 39
2026
Q1 		$706K Buy
17,524
+3,502
+25% +$131K 0.54% 67
2025
Q4 		$488K Buy
14,022
+362
+3% +$28.4K 0.36% 77
2025
Q3 		$1.14M Buy
13,660
+567
+4% +$41K 0.81% 48
2025
Q2 		$961K Buy
13,093
+673
+5% +$48.8K 0.76% 43
2025
Q1 		$1.42M Sell
12,420
-8,061
-39% -$491K 1.16% 34
2024
Q4 		$1.03M Buy
+20,481
New +$1.07M 0.85% 41

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Illumine Investment Management's CORT Position: Q2 2026 in Review

Illumine Investment Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 17,524 shares — an estimated $1.06M sold.

Illumine Investment Management first reported a position in CORT in Q4 2024 and held it in 6 quarters. The position peaked at $1.42M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Illumine Investment Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Illumine Investment Management sold 17,524 Corcept Therapeutics shares in Q2 2026, an estimated $1.06M.
  • Illumine Investment Management first reported a position in Corcept Therapeutics in Q4 2024 and held it in 6 quarters.
  • Illumine Investment Management's Corcept Therapeutics position peaked at $1.42M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Illumine Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.